This epidemiological study aimed to assess the association of pioglitazone use and the risk of developing bladder cancer, as well as 10 additional cancers. These included prostate, female breast, lung, endometrial, colon, non-Hodgkin lymphoma, pancreas, kidney/renal pelvis, rectum and melanoma.